思想的变化:以更好的安全概况准氨基酸β
Katelynn E Krick1, Donna M Wilcock1
1Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA; email: krickk@iu.edu, dwilcock@iu.edu.
Annual review of pharmacology and toxicology
|June 25, 2025
概括
新的阿尔茨海默氏症治疗药物向粉样β有希望,但带有ARIA等风险. 目前正在进行的研究旨在提高安全性,并管理这些副作用,以便更好地治疗患者.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,其特点是认知能力下降.
- 针对白氨酸 (Aβ) 的治疗药物代表了AD治疗的重大进步.
- 目前的Aβ向药物具有与粉样蛋白相关的成像异常 (ARIA) 的风险.
研究的目的:
- 审查目前关于减轻与Aβ向治疗相关的ARIA风险的研究.
- 讨论在接受AD治疗的患者中管理ARIA的临床考虑.
- 探索未来发展更安全的Aβ向治疗方法的方向.
主要方法:
- 最近研究和临床试验的文献综述.
- 对抗体修饰和组合疗法正在进行的研究进行分析.
- 关于ARIA发病率和管理的临床数据的综合.
主要成果:
- 目前正在研究几种降低ARIA的策略,包括抗体工程和组合疗法.
- 对ARIA机制的理解正在得到改善,为风险缓解方法提供了信息.
- 临床管理策略正在发展,以平衡治疗效益与安全问题.
结论:
- 提高Aβ向疗法的安全性对于广泛的AD治疗至关重要.
- 对ARIA缓解和临床管理的持续研究至关重要.
- 开发更安全,更有效的阿尔茨海默病治疗方法是一个活跃和有前途的领域.
更多相关视频
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.4K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.9K
相关概念视频
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:26Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684